CD4 (clone RM4-5), Vβ6 (clone RR4-7), Ki-67 (clone B.56), active caspase-3 (clone C92-605), and CD25 (clone 7D4) were all purchased from BD Biosciences. CD90.1 (Thy1.1, clone HIS51) was purchased from eBiosciences. CD3 (clone 145-2C11), CD8 (clone 53-6.7), CD45.1 (clone A20), CD45.2 (clone 104), TCRγδ (clone GL3), CD326 (clone G8.8), CD19 (clone 6D5), CD90.2 (Thy1.2, clone 53-2.1), CD69 (clone H1.2F3), H2Dd (clone 34-2-12), FOXP3 (clone 150D), IL-10 (clone JES5-16E3), IL-17A (clone TC11-8H10.1), IFN-γ (clone XM1.2), and TNF (clone MP6-XT22) were all purchased from BioLegend. Fixation and permeabilization were undertaken for intracellular staining (BD Fix/Perm Kit; BD Biosciences) and nuclear staining (Fix/Perm Kit; eBiosciences) according to the manufacturer’s instructions. The LIVE/DEAD Fixable Aqua Dead Cell Staining Kit (Invitrogen) was utilized to gate viable cells. Cells were acquired on a BD LSRFortessa and analyzed with FlowJo V9 (Treestar). MR1 tetramers were prepared and used as previously described (7, 8, 11, 75).
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.